The effect of colesevelam treatment on bile acid and lipid metabolism and glycemic control in healthy men

Physiological Research

Volumn 65, Issue 6, 2016, Pages 995-1003

  Blahova T ^a   Peterkova L ^a   Lenicek M ^b   Vlachova M ^a   Zemankova K ^a   Adamkova V ^a   Vitek L ^b   Kovar J ^a  

^a Experimental Medicine   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bile acid; Bile acid sequestrant; Cholesterol 7a hydroxylase; Genetics; LDL cholesterol

Indexed keywords

7 ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; BILE ACID; CHOLAGOGUE; CHOLEST 4 EN 3 ONE; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLESEVELAM; CYP7A1 PROTEIN, HUMAN; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROID HORMONE;

ADULT; ALLELE; BLOOD; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID METABOLISM; MALE; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PILOT STUDY;

ADULT; ALLELES; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CHOLAGOGUES AND CHOLERETICS; CHOLESTENONES; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLESTEROL, LDL; COLESEVELAM HYDROCHLORIDE; FIBROBLAST GROWTH FACTORS; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, GENETIC; THYROID HORMONES;

EID: 85011805091     PISSN: 08628408     EISSN: 18029973     Source Type: Journal    
DOI: 10.33549/physiolres.933276     Document Type: Article

References (31)

1. AXELSON M, BJORKHEM I, REIHNER E, EINARSSON K: The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett 284: 216-218, 1991.
2. BRUFAU G, STELLAARD F, PRADO K, BLOKS VW, JONKERS E, BOVERHOF R, KUIPERS F, MURPHY EJ: Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52: 1455-1464, 2010.
3. CHIANG JY: Bile acids: regulation of synthesis. J Lipid Res 50: 1955-1966, 2009.
4. CHIANG JY: Bile acid metabolism and signaling. Compr Physiol 3: 1191-1212, 2013.
5. COUTURE P, LAMARCHE B: Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond. Curr Opin Lipidol 24: 227-232, 2013.
6. COUTURE P, OTVOS JD, CUPPLES LA, WILSON PW, SCHAEFER EJ, ORDOVAS JM: Association of the A-204C polymorphism in the cholesterol 7alpha-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J Lipid Res 40: 1883-1889, 1999.
7. GOODWIN B, JONES SA, PRICE RR, WATSON MA, MCKEE DD, MOORE LB, GALARDI C, WILSON JG, LEWIS MC, ROTH ME, MALONEY PR, WILLSON TM, KLIEWER SA: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6: 517-526, 2000.
8. HALUZIKOVA D, LACINOVA Z, KAVALKOVA P, DRAPALOVA J, KRIZOVA J, BARTLOVA M, MRAZ M, PETR T, VITEK L, KASALICKY M, HALUZIK M: Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring) 21: 1335-1342, 2013.
9. HOFMAN MK, WEGGEMANS RM, ZOCK PL, SCHOUTEN EG, KATAN MB, PRINCEN HM: CYP7A1 A-278C polymorphism affects the response of plasma lipids after dietary cholesterol or cafestol interventions in humans. J Nutr 134: 2200-2204, 2004.
10. HUBACEK JA, PITHA J, SKODOVA Z, POLEDNE R, LANSKA V, WATERWORTH DM, HUMPHRIES SE, TALMUD PJ: Polymorphisms in CYP-7A1, not APOE, influence the change in plasma lipids in response to population dietary change in an 8 year follow-up; results from the Czech MONICA study. Clin Biochem 36: 263-267, 2003.
11. INSULL W JR: Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 99: 257-273, 2006.
12. KAJINAMI K, BROUSSEAU ME, ORDOVAS JM, SCHAEFER EJ: Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 175: 287-293, 2004.
13. KAJINAMI K, BROUSSEAU ME, ORDOVAS JM, SCHAEFER EJ: A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis 180: 407-415, 2005.
14. KOVAR J, SUCHANEK P, HUBACEK JA, POLEDNE R: The A-204C polymorphism in the cholesterol 7alpha-hydroxylase (CYP7A1) gene determines the cholesterolemia responsiveness to a high-fat diet. Physiol Res 53: 565-568, 2004.
15. LENICEK M, JUKLOVA M, ZELENKA J, KOVAR J, LUKAS M, BORTLIK M, VITEK L: Improved HPLC analysis of serum 7alpha-hydroxycholest-4-en-3-one, a marker of bile acid malabsorption. Clin Chem 54: 1087-1088, 2008a.
16. LENICEK M, KOMAREK V, ZIMOLOVA M, KOVAR J, JIRSA M, LUKAS M, VITEK L: CYP7A1 promoter polymorphism -203A>C affects bile salt synthesis rate in patients after ileal resection. J Lipid Res 49: 2664-2667, 2008b.
17. LRC-CPPT - Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA 251: 351-364, 1984a.
18. LRC-CPPT - Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365-374, 1984b.
19. LIU J, LU H, LU YF, LEI X, CUI JY, ELLIS E, STROM SC, KLAASSEN CD: Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci 141: 538-546, 2014.
20. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
21. OCKENGA J, VALENTINI L, SCHUETZ T, WOHLGEMUTH F, GLAESER S, OMAR A, KASIM E, DUPLESSIS D, FEATHERSTONE K, DAVIS JR, TIETGE UJ, KROENCKE T, BIEBERMANN H, KOHRLE J, BRABANT G: Plasma bile acids are associated with energy expenditure and thyroid function in humans. J Clin Endocrinol Metab 97: 535-542, 2012.
22. SATO H, MACCHIARULO A, THOMAS C, GIOIELLO A, UNE M, HOFMANN AF, SALADIN R, SCHOONJANS K, PELLICCIARI R, AUWERX J: Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem 51: 1831-1841, 2008.
23. SAUTER G, BERR F, BEUERS U, FISCHER S, PAUMGARTNER G: Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 24: 123-126, 1996.
24. SETCHELL KDR, LAWSON AM: Bile acids. In: Mass Spectrometry. LAWSON AM (ed.), Walter de Gruyter, Berlin and New York, 1989, pp 53-125.
25. VÍTEK L, HALUZÍK M: The role of bile acids in metabolic regulation. J Endocrinol 228: R85-R96, 2016.
26. VÍTEK L, NOVOTNY L, ŽÁK A, STAÑKOVÁ B, ZIMA T, POLITO A, CESARE G, ZERBINATI C, IULIANO L: Relationship between serum bilirubin and uric acid to oxidative stress markers in Italian and Czech populations. J Appl Biomed 11: 209-221, 2013.
27. WANG H, CHEN J, HOLLISTER K, SOWERS LC, FORMAN BM: Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3: 543-553, 1999.
28. WANG J, FREEMAN DJ, GRUNDY SM, LEVINE DM, GUERRA R, COHEN JC: Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J Clin Invest 101: 1283-1291, 1998.
29. WATANABE M, HOUTEN SM, WANG L, MOSCHETTA A, MANGELSDORF DJ, HEYMAN RA, MOORE DD, AUWERX J: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113: 1408-1418, 2004.
30. WATANABE M, HOUTEN SM, MATAKI C, CHRISTOFFOLETE MA, KIM BW, SATO H, MESSADDEQ N, HARNEY JW, EZAKI O, KODAMA T, SCHOONJANS K, BIANCO AC, AUWERX J: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489, 2006.
31. ZIEVE FJ, KALIN MF, SCHWARTZ SL, JONES MR, BAILEY WL: Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29: 74-83, 2007.